Synopsis: Shares of Glenmark Pharmaceuticals Limited were in focus after its subsidiary Glenmark Specialty SA received approval from the U.S. Food and Drug Administration for a respiratory inhalation drug, enabling the company to target a $520 million U.S. market with 180-day generic exclusivity.
The shares of this company, which is a global research-led pharmaceutical company with a presence across generics, Specialty and OTC businesses with operations in several countries, were in focus today after the company got a USFDA approval for its respiratory-based medication targeting a $500 million-plus market.
With a market cap of Rs 57,500 crore, the shares of Glenmark Pharmaceuticals Ltd are trading at Rs 2,037 and are trading at a PE of 21.2 compared to their industry PE of 27.7. The shares have given a return of more than 300% in the last 5 years.
About the USFDA approval
Shares of Glenmark Pharmaceuticals Limited have been in the limelight as the company’s subsidiary, Glenmark Specialty SA, has received final approval from the United States’ Food and Drug Administration for the marketing of Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, which belongs to the respiratory class of generic drugs used for the management of conditions such as asthma. The approval has strengthened the company’s presence in the United States’ respiratory market and marks the latest regulatory milestone for the company’s inhalation therapy business.
The approved product has been found to be bioequivalent and therapeutically equivalent to the reference-listed drug FloVent HFA Inhalation Aerosol, which is developed by GlaxoSmithKline plc. The company has been awarded the Competitive Generic Therapy (CGT) designation and recognised as the first approved applicant for the marketing of the product, thus making the company eligible for 180 days of market exclusivity upon the launch of the product in the United States.
The product will be marketed and distributed in the US by Glenmark Pharmaceuticals Inc., USA. The commercialisation of the product is expected to commence in March 2026. This is expected to improve the company’s position in the inhalation therapy market, which is a complex market requiring advanced drug delivery systems and approvals. This approval also marks Glenmark’s commitment to developing its specialty and respiratory drugs portfolio and expanding its presence in the global market.
The market size of the FloVent HFA Inhalation Aerosol 44 mcg product was around $520.1 million in the 12 months leading up to January 2026. This is a significant market size and is expected to generate revenue for Glenmark during its exclusivity period, especially as it is entering the market as a first generic competitor in the market.
This approval is also a testament to Glenmark’s capabilities in developing complex inhalation products and approvals in the US market. The company operates in 80+ countries and focuses on respiratory, dermatology, and oncology drugs and is continually improving its position in the global pharmaceutical market as a leader in innovation and specialty generics.
Financials
The revenue from operations for the company stood at Rs 3,901 crore in Q3 FY26 compared to the Q3 FY25 revenue of Rs 3,388 crore, up by about 15 per cent YoY. Similarly, the net profit stood at Rs 403 crore in Q3 FY26, up compared to the Rs 348 crore profit in Q3 FY25.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Glenmark Pharma Targets $520 Million U.S. Respiratory Market After FDA Approval appeared first on Trade Brains.